TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01663259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
Study: NCT04688840

Intervention type: PROCEDURE
Intervention: hip arthropalsty
Description: follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method

Intervention type: PROCEDURE
Intervention: hip arthropalsty
Description: follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
Study: NCT04425499

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Learning running subcuticular sutures on the Gamified Educational Network
Description: Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning running subcuticular sutures on the Gamified Educational Network
Description: Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning running subcuticular sutures on the Gamified Educational Network
Description: Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning running subcuticular sutures on the Gamified Educational Network
Description: Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
Study: NCT02872415

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood puncture site
Description: Blood puncture site

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood puncture site
Description: Blood puncture site
Study: NCT00804427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil (90% triglycerides)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil (60% triglycerides)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil (ethyl esters)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy oil
Study: NCT03925792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: diet, sleep, exercise and mindfulness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: diet, sleep, exercise and mindfulness
Study: NCT03125889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AquaBeam System
Description: The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
Study: NCT00563797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine
Description: mecamylamine 10mg/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT02303795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 \> years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 \> years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day.
Study: NCT02343653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and strength training
Description: All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training.
Study: NCT01905813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB040093
Description: Escalating doses starting at 100 mg every day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB040093 + itacitinib
Description: INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
Study: NCT02343653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.
Study: NCT00139451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pediasure
Description: With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GH
Description: Growth Hormone will be 0.3mg/kg/week, given SC once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GH
Description: Growth Hormone will be 0.3mg/kg/week, given SC once daily.
Study: NCT02666768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Description: gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
Study: NCT03524443

Intervention type: BEHAVIORAL
Intervention: Art Therapy treatment
Description: The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing
Study: NCT00882752

Intervention type: PROCEDURE
Intervention: molecular analysis
Description: bowel disease
Study: NCT03110237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Balance Training (BT) class
Description: Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fallproof Balance Training (BT) class
Description: There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
Study: NCT02031861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine CR tablets (Xin Ran)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine CR tablets (Adalat)
Study: NCT00535210

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cardiovascular training
Description: The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Balance training
Description: The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
Study: NCT03695900

Intervention type: OTHER
Group type: OTHER
Intervention: Targeting SpO2 at 93-95%
Description: FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours

Intervention type: OTHER
Group type: OTHER
Intervention: Targeting SpO2 at 93-95%
Description: FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours

Intervention type: OTHER
Group type: OTHER
Intervention: Targeting SpO2 at 90-92%
Description: FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Targeting SpO2 at 90-92%
Description: FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
Study: NCT04127279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cream
Description: The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.~The placebo cream is devoid of the essential oils

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cream
Description: The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.~The placebo cream is devoid of the essential oils
Study: NCT01518322

Intervention type: DEVICE
Intervention: NIOX MINO®
Description: Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
Study: NCT04062669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
Description: Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) low dose formulation, administered intramuscularlyat Days 1 and 61.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
Description: Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 1 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
Description: Subjects in the Lower dose (Lrd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lower dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
Description: Subjects in the Lowest dose (Ltd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lowest dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RabAvert
Description: Subjects in the RabAvert Group will receive 2 doses of RabAvert vaccine, administered intramuscularly, at Days 1 and 61.
Study: NCT03521388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take care of your mood (CUIDA TU ANIMO in Spanish)
Description: The adolescents will be registered in the Website www.cuidatuanimo.org

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
Study: NCT03901677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-chi training
Description: Group exercise apply with physiotherapist
Study: NCT03694080

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Patients with potentially curable colorectal rectal cancer will be treated preoperatively
Study: NCT02338648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-131 1.5% TDS
Description: Active transdermal patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TDS
Description: Placebo transdermal patch for blinding
Study: NCT04304989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth program
Description: mobile health applications

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: usual care
Study: NCT03710408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous hydration
Description: Participants assigned to the intravenous hydration arm will receive their hydration therapy through an intravenous access. This access will be achieved by inserting a BD VenflonTM Pro Safety - 22G in a vein in the dorsal side of the hand or further up the forearm. If the participants is suspected of becoming delirious and at risk of removing the cannula from the hand/forearm, it may be inserted at the dorsal side of the foot. The clinical staff judge this risk and decide site of placement.~Furthermore, a sham subcutaneous access device BD Saf-T-Intima™ Integrated Safety Catheter System will be placed on the abdomen without piercing the skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcutaneous hydration
Description: Participants assigned to the subcutaneous hydration arm will receive their hydration therapy through a subcutaneous access. This access will be achieved by placing a BD Saf-T-Intima™ Integrated Safety Catheter System on the abdomen or, alternatively if the participants is suspected of becoming delirious and at risk of removing the needle, it will be placed on the back at the scapular region.~Furthermore, a sham IV access device BD VenflonTM Pro Safety - 22G will be placed on the dorsal side of the hand without piercing the skin.
Study: NCT02246751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Training for trunk control
Description: Orthotics Research and Locomotor Research Unit (ORLAU) standers will be custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
Study: NCT02301169

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heat pain stimuli A

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of T4P1001 capsules
Description: This treatment is given as add on therapy to patients' regular analgesic

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Heat pain stimuli B

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Video B

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Administration of placebo capsules
Description: This treatment is given as add on therapy to patients' regular analgesic
Study: NCT04573322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate
Description: TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
Study: NCT01996930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haelan tape (steroid impregnated tape)
Description: Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
Study: NCT00659711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Januvia (Sitagliptin) 100 mg
Description: The first group will be started on 100 mg sitagliptin daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will be placed on a placebo for 12 weeks.
Study: NCT03126773

Intervention type: DRUG
Intervention: BAY86-4891
Description: Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
Study: NCT03295838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment
Description: See Arm description
Study: NCT00075816

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic bone marrow transplantation
Description: Bone marrow transplant from HLA compatible unrelated donors.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood stem cell transplantation
Description: Peripheral blood transplant from HLA compatible unrelated donors.
Study: NCT04421599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Necessity of Aspiration
Description: The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Necessity of Aspiration
Description: The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered.
Study: NCT02483676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill plus anklebot
Description: This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill only
Description: This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period